Wet AMD

Biosimilar

Diabetic Eye Awareness

Diabetic Macular Edema

Diabetic Retinopathy

Geographic Atrophy

Imaging

Inherited Retinal Diseases

Europe

Ophthalmology

Retina Technology

Retinal Surgery

Uveitis

News

All News

Blogs

Media

All Videos

Case-Based Roundtable Series

Expert Interviews

Eyeviews

Insights

Medical World News

Podcasts

Rapid Readouts

Viewpoints

Conference

Conference Coverage

Conference Listing

Publications

Modern Retina Digital Edition

Supplements And Featured Publications

Resources

Between the Lines

CME/CE

EYLEA 8mg for nAMD and DME Treatment

Partners

Subscribe

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Modern Retina | Ophthalmology News, Events & Expert Insights

Facebook

LinkedIn

Spotlight

Clinical

1rem

View

Innovations for Sustained Anti-VEGF Delivery in Retinal Diseases 

clinical

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies

Video content above is prompted by the following:

If TKIs become available, how would this impact the relative benefits of PDS?

Videos

Panelists discuss how the chronic nature of retinal diseases requires consistent VEGF suppression through regular anti-VEGF injections, but this treatment burden leads to challenges including patient compliance, health care resource strain, and quality of life impacts from frequent office visits.

Need for Sustained Delivery of Anti-VEGF in Retinal Diseases

Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating noninferior vision outcomes compared with monthly ranibizumab injections while reducing treatment burden through 6-month refill intervals.

Overview of Port Delivery System With Ranibizumab

Panelists discuss how successful port delivery system (PDS) implantation requires careful patient selection and meticulous surgical technique to minimize complications like vitreous hemorrhage and endophthalmitis, with certain patients being poor candidates due to factors such as active inflammation, thin sclera, or glaucoma filtering devices.

Adverse Effects Associated With PDS and Surgical Considerations

Panelists discuss how surgeons must complete specialized training and certification through the risk evaluation and mitigation strategy program to perform port delivery system implantation, which requires a sterile operating room environment and specific surgical instruments designed for the procedure.

Navigating the Surgical Learning Curve for Effective PDS Implantation

Panelists discuss how patients experiencing frequent anti-VEGF treatment burdens with 4- to 8-week intervals between injections are ideal candidates for PDS as an alternative delivery method.

Patient Selection for PDS

Panelists discuss how the port delivery system (PDS) refill procedure, while performed in an office setting, involves a different technique of accessing and replenishing the implant’s drug reservoir through the conjunctiva and requires specialized training compared with standard intravitreal injections.

Technique for Refilling the PDS

Panelists explore how the introduction of tyrosine kinase inhibitors (TKIs) could affect the perceived benefits of the port delivery system, as these agents may offer an alternative approach to reducing injection burden while potentially providing broader therapeutic effects.

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF  Therapies

Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies

EP: 1.Need for Sustained Delivery of Anti-VEGF in Retinal Diseases

EP: 2.Overview of Port Delivery System With Ranibizumab

EP: 3.Adverse Effects Associated With PDS and Surgical Considerations

EP: 4.Navigating the Surgical Learning Curve for Effective PDS Implantation

EP: 5.Patient Selection for PDS

EP: 6.Technique for Refilling the PDS

EP: 7.Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies

Newsletter